Bursin as an adjuvant is a potent enhancer of immune response in mice immunized with the JEV subunit vaccine

Adjuvants play an important role in the formulation of effective and appropriate vaccines. A series of synthetic bursin and bursin-like peptides was heterologously expressed in Escherichia coli. The use of bursin as an adjuvant enhanced the specific immune responses of mice immunized with a recombinant Japanese encephalitis virus E-binding domain (JEV E-BD) fusion protein. The effect was determined in the form of protective anti-JEV E titers, antibodies (IgG1 and IgG2a), spleen cell lymphocyte proliferation, the levels of interferon-γ and interleukin-4 cytokines, and the T-lymphocyte sub-type composition. The IgG2a titer and interferon-γ level suggested that the E-BD protein potentiates the Th1 immune response. These responses were changed when the immunogen was combined with one of the synthetic peptides as adjuvant. JEV-neutralization assay results show that the presence of bursin significantly enhance the JEV-neutralizing titer. We conclude that bursin as an adjuvant is a potent enhancer of immune response in mice immunized with the JEV subunit vaccine, and represents a promising adjuvant for vaccination.